Efficacy of direct-acting antiviral therapy for hepatitis C viral infection. Real-life experience in Bahrain

被引:6
作者
Abdulla, Maheeba [1 ]
Ali, Hamed [2 ]
Nass, Hafsa [2 ]
Khamis, Jawad [2 ]
AlQamish, Jehad [1 ]
机构
[1] Salmaniya Med Complex, Gastroenterol & Hepatol, Manama, Bahrain
[2] Salmaniya Med Complex, Med Dept, Manama, Bahrain
关键词
HCV; DAAs; treatment; sustained viral response; cirrhosis; liver disease; SUSTAINED VIROLOGICAL RESPONSE; DACLATASVIR PLUS SOFOSBUVIR; GENOTYPE; 3; INFECTION; WORLD EFFECTIVENESS; INTERFERON THERAPY; TREATMENT-NAIVE; HCV INFECTION; VIRUS; LEDIPASVIR/SOFOSBUVIR; RIBAVIRIN;
D O I
10.2147/HMER.S190967
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Purpose: The introduction of direct-acting antivirals (DAAs) has revolutionized the treatment of chronic hepatitis C viral (HCV) infection. This study aims to establish real-world treatment efficacy of Sofosbuvir-based (SOF-B) and Ombitasvir/Paritaprevir/Ritonavir-based (OPR-B) regimens. Patients and methods: This prospective, non-randomized observational real-life study was conducted in Salmaniya Medical Complex, Bahrain, and included consecutive patients with chronic HCV infection (genotypes 1-4) who were treated with direct-acting antivirals. Sustained virologic response to therapy was assessed at week 12 post end of treatment (SVR12). Results: Of the 167 patients included, 60.5% (n=101) were treated with SOF-B and 39.5% (n=66) with OPR-B regimens for 12 weeks (n=148; 88.6%) or 24 weeks (n=19; 11.4%). SVR12 was achieved in 156 (93.4%) patients, 4 patients failed to achieve SVR despite completion of treatment, and 7 patients discontinued treatment due to non-compliance and were included in the analysis on an intention-to-treat basis. There was no difference between SOF-B and OPR-B regimens (95/101; 94.1%) and (61/66; 92.4%), respectively (p=0.68). However, SVR12 rates were significantly higher in patients without liver cirrhosis (103/104; 99.0%) compared to patients with cirrhosis (53/63; 84.1%; p<0.001), and in patients who received 12-week-regimen (141/148; 95.3%) compared to those who received 24-week regimen (15/19; 78.9%; p<0.024). However, logistic regression analysis identified cirrhosis at baseline to be the only independent predictor of non-SVR12 (OR: 16.1, 95% confidence interval 1.96-131.91, p=0.01). Apart from Hb, INR, and ALP, all other laboratory parameter improved following treatment (p<0.05). Conclusion: Both SOF-B and OPR-B regimens achieved high SVR12 rates in this real-life cohort of patients with chronic HCV infection, similar to what is reported in other real-world studies. Cirrhosis was the only independent predictor of poor response.
引用
收藏
页码:69 / 78
页数:10
相关论文
共 29 条
[1]   RETRACTED: Efficacy and safety of sofosbuvir plus ribavirin for treatment of cirrhotic patients with genotype 4 hepatitis C virus in real-life clinical practice (Retracted Article) [J].
Abd-Elsalam, Sherief ;
Sharaf-Eldin, Mohamed ;
Soliman, Shaimaa ;
Elfert, Asem ;
Badawi, Rehab ;
Ahmad, Youssef K. .
ARCHIVES OF VIROLOGY, 2018, 163 (01) :51-56
[2]   Recovery, persistence, and sequelae in hepatitis C virus infection: A perspective on long-term outcome [J].
Alter, HJ ;
Seeff, LB .
SEMINARS IN LIVER DISEASE, 2000, 20 (01) :17-35
[3]   A 5-year prospective study of the late resolution of chronic hepatitis C after antiviral therapy [J].
Annicchiarico, B. E. ;
Siciliano, M. ;
Avolio, A. W. ;
Grillo, R. L. ;
Bombardieri, G. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2007, 25 (09) :1039-1046
[4]   Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C [J].
Arase, Yasuji ;
Ikeda, Kenji ;
Suzuki, Fumitaka ;
Suzuki, Yoshiyuki ;
Saitoh, Satoshi ;
Kobayashi, Masahiro ;
Akuta, Norio ;
Someya, Takashi ;
Koyama, Rikako ;
Hosaka, Tetsuya ;
Sezaki, Hitomi ;
Kobayashi, Mariko ;
Kumada, Hiromitsu .
INTERVIROLOGY, 2007, 50 (01) :16-23
[5]  
Ascione Antonio, 2007, Dig Liver Dis, V39 Suppl 1, pS4, DOI 10.1016/S1590-8658(07)80003-X
[6]   Identification of the Best Direct-Acting Antiviral Regimen for Patients With Hepatitis C Virus Genotype 3 Infection: A Systematic Review and Network Meta-analysis [J].
Berden, Floor A. C. ;
Aaldering, Bryan R. R. Z. ;
Groenewoud, Hans ;
IntHout, Joanna ;
Kievit, Wietske ;
Drenth, Joost P. H. .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2017, 15 (03) :349-359
[7]  
Bichoupan Kian, 2017, World J Virol, V6, P59, DOI 10.5501/wjv.v6.i4.59
[8]   Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study [J].
Blach, Sarah ;
Zeuzem, Stefan ;
Manns, Michael ;
Altraif, Ibrahim ;
Duberg, Ann-Sofi ;
Muljono, David H. ;
Waked, Imam ;
Alavian, Seyed M. ;
Lee, Mei-Hsuan ;
Negro, Francesco ;
Abaalkhail, Faisal ;
Abdou, Ahmed ;
Abdulla, Maheeba ;
Abou Rached, Antoine ;
Aho, Inka ;
Akarca, Ulus ;
Al Ghazzawi, Imad ;
Al Kaabi, Saad ;
Al Lawati, Faryal ;
Al Namaani, Khalid ;
Al Serkal, Youssif ;
Al-Busafi, Said A. ;
Al-Dabal, Layla ;
Aleman, Soo ;
Alghamdi, Abdullah S. ;
Aljumah, Abdulrahman A. ;
Al-Romaihi, Hamad E. ;
Andersson, Monique I. ;
Arendt, Vic ;
Arkkila, Perttu ;
Assiri, Abdullah M. ;
Baatarkhuu, Oidov ;
Bane, Abate ;
Ben-Ari, Ziv ;
Bergin, Colm ;
Bessone, Fernando ;
Bihl, Florian ;
Bizri, Abdul R. ;
Blachier, Martin ;
Blasco, Antonio J. ;
Mello, Carlos E. Brandao ;
Bruggmann, Philip ;
Brunton, Cheryl R. ;
Calinas, Filipe ;
Chan, Henry L. Y. ;
Chaudhry, Asad ;
Cheinquer, Hugo ;
Chen, Chien-Jen ;
Chien, Rong-Nan ;
Choi, Moon Seok .
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2017, 2 (03) :161-176
[9]   The natural course of HCV infection and the need for treatment [J].
Bruno, Savino ;
Facciotto, Corinna .
ANNALS OF HEPATOLOGY, 2008, 7 (02) :114-119
[10]   Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C [J].
Buggisch, Peter ;
Vermehren, Johannes ;
Mauss, Stefan ;
Guenther, Rainer ;
Schott, Eckart ;
Pathil, Anita ;
Boeker, Klaus ;
Zimmermann, Tim ;
Teuber, Gerlinde ;
Vornkahl, Heike-Pfeiffer ;
Simon, Karl-Georg ;
Niederau, Claus ;
Wedemeyer, Heiner ;
Zeuzem, Stefan .
JOURNAL OF HEPATOLOGY, 2018, 68 (04) :663-671